Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca
  • Sanofi
  • Amgen
  • Servier

This publication has 23 references indexed in Scilit: